NASDAQ:ADIL Adial Pharmaceuticals Q4 2024 Earnings Results & Report $3.14 +0.14 (+4.67%) Closing price 10/15/2026 04:00 PM EasternExtended Trading$3.14 +0.00 (+0.13%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Adial Pharmaceuticals beat analyst earnings expectations in its Q4 2024 results, released March 4, 2025. The company reported EPS of -$3.75 versus the -$9.50 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 4, 2025TimeBefore Market OpensConference Call7:00 AM ET Adial Pharmaceuticals EPS ResultsActual EPS-$3.75Consensus EPS -$9.50Beat/MissBeat by +$5.75One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersAdial Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsAdial Pharmaceuticals' Q3 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Adial Pharmaceuticals Q4 2024 Earnings FAQ Did Adial Pharmaceuticals beat earnings estimates for Q4 2024? Adial Pharmaceuticals (NASDAQ:ADIL) reported earnings of -$3.75 per share for Q4 2024, beating the consensus estimate of -$9.50. The report was announced on Tuesday, March 4, 2025. When is Adial Pharmaceuticals' next earnings date? Adial Pharmaceuticals' next earnings date is estimated for Wednesday, November 18, 2026. MarketBeat tracks confirmed and estimated earnings dates for Adial Pharmaceuticals on the company's earnings history page. Adial Pharmaceuticals Earnings HeadlinesAdial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)September 30, 2026 | globenewswire.comAdial Pharmaceuticals Announces Board AppointmentsSeptember 18, 2026 | marketscreener.comMI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any regular brokerage account gives investors exposure to SpaceX and 66 of its neighbors, without an IPO allocation. He is also naming two space stocks he would consider dumping before December, plus a $14 stock that Elon has personally put his name on. | Behind the Markets (Ad)Adial Shareholders Approve Key Proposals, Meeting AdjournedSeptember 18, 2026 | tipranks.comAdial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)August 25, 2026 | globenewswire.comAdial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business UpdateAugust 17, 2026 | globenewswire.comSee More Adial Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Adial Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adial Pharmaceuticals and other key companies, straight to your email. Email Address About Adial PharmaceuticalsAdial Pharmaceuticals (NASDAQ:ADIL) (NASDAQ: ADIL) is a clinical-stage biopharmaceutical company focused on developing treatments for addiction and related disorders. The company uses a genetically targeted approach intended to identify patients who may be more likely to respond to specific therapies. Adial’s lead product candidate, AD04, is an investigational formulation of ondansetron, a selective serotonin-3 receptor antagonist. It is being developed for the treatment of alcohol use disorder, with the goal of reducing alcohol consumption and supporting abstinence in genetically selected patient populations. The company has also evaluated the potential application of its platform in other addictive disorders, including smoking cessation. Founded in 2011, Adial Pharmaceuticals is headquartered in Charlottesville, Virginia. Its development programs are subject to clinical testing and regulatory review, and the company’s therapies are not approved for commercial use unless and until applicable regulatory requirements are satisfied. William M. Stilley has served as the company’s chief executive officer.View Adial Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
